Table 4.

BIBF 1120 and pemetrexed PK parameters

A
BIBF 1120 day 2, TC 2200 mg bid (n = 8)
gMeangCV (%)
AUC0-24 (ng h/mL)308*43.9*
Cmax (ng/mL)50.481.2
tmax (h)2.001.00-23.8
t1/2 (h)12.1*43.4*
CL/F (mL/min)8,180*33.5*
Vz/F (L)8,580*56.0*
B
Pemetrexed day 1, TC 2 (MTD)TC 2 (n = 8)
gMeangCV (%)
AUC0-24 (μg h/mL)20017.1
Cmax (μg/mL)98.021.8
tmax (h)0.2750.0160-0.500
t1/2 (h)3.7131.6
CL (L/h)4.7824.2
Vz (liter)25.631.1
Vss (liter)15.418.9

NOTE: A, comparison of BIBF 1120 PK parameters for the 200 mg bid BIBF 1120 dose group (MTD). B, PK parameters (gMean and gCV%) of pemetrexed after administration of 500 mg/m2 pemetrexed over 8 to 15 min on day 1 (TC 2) after continuous treatment of 200 mg bid BIBF 1120 (days 2-21 of TC 1).

  • *n = 6.

  • Median and range.

  • n = 7.